DGX-001 is under clinical development by Viage Therapeutics and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DGX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DGX-001 is under development for the treatment of major depressive disorder. The drug candidate is a peptide. It acts by targeting vasopressin V1a receptor. It is administered through oral route.
Viage Therapeutics overview
Viage Therapeutics engaged in research and development of novel neurotherapeutics, oral drug candidates, small molecules and peptides for the treatment of inflammatory, depression, anxiety and cognitive impairment diseases. The company is headquartered in Redwood City, California, the US.
For a complete picture of DGX-001’s drug-specific PTSR and LoA scores, buy the report here.